{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:12:59Z","timestamp":1760908379101},"reference-count":0,"publisher":"American Diabetes Association","issue":"4","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1997,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To investigate whether long-acting somatostatin (SMS) can suppress renal hyperfiltration in patients with IDDM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>A double-blind, randomized treatment of nine patients with IDDM was used. Selection criteria were renal hyperfiltration (glomerular filtration rate [GFR] \u2265 129 ml \u00b7 min\u22121 \u00b7 1.73 m2) and absence of hypertension and macroalbuminuria. Treatment was either with a long-acting SMS analog (Somatulin, 30 mg) or with placebo, given by intramuscular injections every 10 days for 9 months. GFR, effective renal plasma flow (ERPF), IGF-I, and 24-h growth hormone (GH) profiles were used as evaluation parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Five patients were randomized to Somatulin, four patients to placebo. One of the patients treated with Somatulin stopped after 3 months because of persistent abdominal discomfort after the injections. Somatulin treatment for 3 months lowered GFR and ERPF compared with placebo (P &amp;lt; 0.05). After 9 months, the differences were no longer significant. After 3 months, IGF-I concentrations were decreased in all Somatulin-treated patients. GH secretion tended to increase in the placebo group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The administration of long-acting Somatulin to patients with IDDM and renal hyperfiltration leads to only a temporary reduction of ERPF\/GFR.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/diacare.20.4.632","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"632-636","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":16,"title":["Effect of Long-Acting Somatostatin Analog (Somatulin) on Renal Hyperfiltration in Patients With IDDM"],"prefix":"10.2337","volume":"20","author":[{"given":"Marloes L","family":"Jacobs","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, Erasmus University, Rotterdam\u2008The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans H M","family":"Derkx","sequence":"additional","affiliation":[{"name":"Internal Medicine I, Erasmus University\u2008Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Stijnen","sequence":"additional","affiliation":[{"name":"University Hospital Dijkzigt, Department of Biostatistics, Erasmus University\u2008Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven W J","family":"Lamberts","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Erasmus University, Rotterdam\u2008The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob F A","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Erasmus University, Rotterdam\u2008The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/20\/4\/632\/584113\/20-4-632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/20\/4\/632\/584113\/20-4-632.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T14:32:29Z","timestamp":1647095549000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/20\/4\/632\/22370\/Effect-of-Long-Acting-Somatostatin-Analog"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,4,1]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.20.4.632","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,4,1]]}}}